Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Hiroshi, Sootome"'
Autor:
Satoru Ito, Sachie Otsuki, Hirokazu Ohsawa, Atsushi Hirano, Hideki Kazuno, Satoshi Yamashita, Kosuke Egami, Yoshihiro Shibata, Ikuo Yamamiya, Fumiaki Yamashita, Yasuo Kodama, Kaoru Funabashi, Hiromi Kazuno, Toshiharu Komori, Satoshi Suzuki, Hiroshi Sootome, Hiroshi Hirai, Takeshi Sagara
Publikováno v:
ACS Medicinal Chemistry Letters. 14:396-404
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::270fb283ac492b9da7e9ad16d06a308b
https://doi.org/10.1021/acsmedchemlett.3c00006
https://doi.org/10.1021/acsmedchemlett.3c00006
(a) Structure of TAS-119. (b) IC50 value for each recombinant Aurora kinase.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a56bf2543d4ed85e4e10b7a908001106
https://doi.org/10.1158/1535-7163.22518504.v1
https://doi.org/10.1158/1535-7163.22518504.v1
Combination Index scores (CI50 and CI75) are shown in the indicated cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d490357e67a68c24ebb9dbc21c20a01
https://doi.org/10.1158/1535-7163.22518483.v1
https://doi.org/10.1158/1535-7163.22518483.v1
TAS-119 is a novel orally active, selective inhibitor of Aurora kinase A identified as a clinical candidate for efficacy testing in combination with taxanes. In vitro, TAS-119 enhanced cell growth inhibition of paclitaxel in multiple human cancer cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a93d7fce7bb81de78876d90f6ddecb9
https://doi.org/10.1158/1535-7163.c.6541941
https://doi.org/10.1158/1535-7163.c.6541941
Supplementary Material & Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1129c9b9987df937b36c8a4e7137da67
https://doi.org/10.1158/1535-7163.22518489.v1
https://doi.org/10.1158/1535-7163.22518489.v1
Autor:
Hiroshi Hirai, Kazuhiko Yonekura, Kenichi Matsuo, Masakazu Yashiro, Kaoru Funabashi, Sachie Otsuki, Hirokazu Ohsawa, Satoru Ito, Takeshi Sagara, Akihiro Miura, Kimihiro Ito, Yayoi Fujioka, Hiroaki Ochiiwa, Kenjiro Ito, Hidenori Fujita, Hiroshi Sootome
Appendix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dbc88955cc17f0ae931acd6bbfa8f80
https://doi.org/10.1158/0008-5472.22425297
https://doi.org/10.1158/0008-5472.22425297
Autor:
Hidehito Kotani, Bo-Sheng Pan, Pradip K. Majumder, Harold Hatch, Yoko Ueno, Kyoko Tsujioka, Shunsuke Taguchi, Katsuyoshi Miyama, Yoko Nakatsuru, Hiroshi Sootome, Hiroshi Hirai
Supplementary Data from MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2de18f2eea7f6ca1d5c2c31985f304cd
https://doi.org/10.1158/1535-7163.22486085.v1
https://doi.org/10.1158/1535-7163.22486085.v1
Autor:
Hiroshi Hirai, Kazuhiko Yonekura, Kenichi Matsuo, Masakazu Yashiro, Kaoru Funabashi, Sachie Otsuki, Hirokazu Ohsawa, Satoru Ito, Takeshi Sagara, Akihiro Miura, Kimihiro Ito, Yayoi Fujioka, Hiroaki Ochiiwa, Kenjiro Ito, Hidenori Fujita, Hiroshi Sootome
FGFR signaling is deregulated in many human cancers, and FGFR is considered a valid target in FGFR-deregulated tumors. Here, we examine the preclinical profile of futibatinib (TAS-120; 1-[(3S)-[4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2023864d5d1897373c596d5113c5a2b7
https://doi.org/10.1158/0008-5472.c.6512004.v1
https://doi.org/10.1158/0008-5472.c.6512004.v1
Autor:
Hidekazu Takahashi, Norio Masuko, Hiroshi Sootome, Tetsuya Sugimoto, Akihiro Hashimoto, Hiroshi Hirai, Morihiro Mitsuya, Naoya Fujita, Shinji Mizuarai, Hiroto Fukushima, Takamasa Suzuki, Akihiro Miura, Kimihiro Ito, Yoshihiro Uto
Publikováno v:
Investigational New Drugs. 39:724-735
Aurora kinase A, a mitotic kinase that is overexpressed in various cancers, is a promising cancer drug target. Here, we performed preclinical characterization of TAS-119, a novel, orally active, and highly selective inhibitor of Aurora A. TAS-119 sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f49e8e3b888cc31f99255c53d48b11
https://doi.org/10.1007/s10637-020-01019-9
https://doi.org/10.1007/s10637-020-01019-9
Autor:
Yayoi Fujioka, Kaoru Funabashi, Kazuhiko Yonekura, Hirokazu Ohsawa, Kimihiro Ito, Kenichi Matsuo, Kenjiro Ito, Akihiro Miura, Hiroshi Hirai, Masakazu Yashiro, Takeshi Sagara, Satoru Ito, Hiroaki Ochiiwa, Hiroshi Sootome, Sachie Otsuki, Hidenori Fujita
Publikováno v:
Cancer Research. 80:4986-4997
FGFR signaling is deregulated in many human cancers, and FGFR is considered a valid target in FGFR-deregulated tumors. Here, we examine the preclinical profile of futibatinib (TAS-120; 1-[(3S)-[4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b772710ff26e5029bb7144c4eda081a
https://doi.org/10.1158/0008-5472.can-19-2568
https://doi.org/10.1158/0008-5472.can-19-2568